Interview with Manfred Paul, Director, Naari AG Russia/CIS
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
Address:
Tel: +41 615880242
Web: http://www.naari.ch/
NAARI aspires to be a world leader in the area of female healthcare, providing medical solutions from puberty to menopause. Our aim is to be the world’s first 100% integrated generic female health pharmaceutical company. This implies complete involvement in every step of production, going from plant extract to final dosage forms. By giving our stake holders cutting edge expertise, we set the standard for female health products, globally.
NAARI’s core expertise lies in manufacturing Active Pharmaceutical Ingredients (APIs) and Formulations focusing exclusively on the female health segment with a special emphasis on high active female hormones.
The nature of our work and our dedication to fulfilling our vision demands a deeply ingrained set of values that are integral to our processes and operations. Here, we affirm those values by providing high quality, affordable and innovative solutions.
APIs, Formulations, Intermediates, Diagnostics
Since our last report on Russia in 2007, there has been much emphasis placed on developing local industry, and reducing the nation’s reliance on imported pharmaceutical products. How do you…
You founded this business in 2003, and it has since grown to encompass five offices and over 250 experts. Can you tell our readers a bit about the history behind…
The following is an interview with Dr. Smirnov, as well as Dr. Dmitri Pavlovich, Director, Clinical Operations Russia Quintiles very recently announced the launch of its first commercial project in…
The following is an interview with Dr. Pavlovich, as well as Dr. Sergey Smirnov, Director, Business Development and Operations, CEE, CIS and Russia Quintiles very recently announced the launch of…
GSK CEO Andrew Witty has said that GSK must move away from selling “white pills in Western markets” in order to offset widespread generic erosion. This means diversifying the company’s…
The following is joint interview of Mr. Vayntrub and Regina Karymova, General Manager of Invar Mr. Vayntrub, you founded Invar in 1991, and began to capitalize on foreign investment in…
Pepeliaev, Goltsblat & Partners and the major UK firm Berwin Leighton Paisner (BLP). It calls itself the first international Russian law firm. Can you explain to our readers the rationale…
You have lead this company since its beginnings in 2003, when it acquired ICN pharmaceuticals. In 2007, Pharmstandard carried out an IPO of 43% of its shares. How has the…
You were working for GSK since 2003 before joining Galderma this year. Some within the industry might view Galderma as a step down from the third-ranked pharmaceutical company in the…
Janssen recently signed memorandums of understanding with both the Skolkovo Foundation and ChemRar. Can you describe the strategic parameters and intended outcomes of these agreements? How do they factor into…
Mr. Demidov, you are one of the pioneers of market research studies in Russia. There is a quote you like to use: ‘Market research is a business in the United…
How would you describe CMS’s own presence in the life sciences field in Russia, and what unique competitive advantages does the firm bring to this area of practice? Over the…
With the announcement of the Pharma 2020 strategy to develop the domestic pharmaceutical industry, multinational companies have pledged an excess of $1Bn in investment into local infrastructure. Servier, however, preempted…
See our Cookie Privacy Policy Here
